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ABASTRACT 
Background: Little is known about follow-up care attendance of adolescent survivors of 
childhood cancer, and which factors foster or hinder attendance. Attending follow-up care is 
especially important for adolescent survivors to allow for a successful transition into adult care. 
We aimed to (1) describe the proportion of adolescent survivors attending follow-up care, (2) 
describe adolescents’ health beliefs, and (3) identify the association of health 
beliefs,demographic and medical factors with follow-up care attendance. 
Procedure: Of 696 contacted adolescent survivors diagnosed with cancer at ≤16 years of age, ≥5 
years after diagnosis, and aged 16–21 years at study, 465 (66.8%) completed the Swiss 
Childhood Cancer Survivor Study questionnaire. We assessed follow-up care attendance and 
health beliefs, and extracted demographic and medical information from the Swiss Childhood 
Cancer Registry. Cross-sectional data were analyzed using descriptive statistics and logistic 
regression models. 
Results: Overall, 56% survivors reported attending follow-up care. Most survivors (80%) rated 
their susceptibility for late effects as low and believed that follow-up care may detect and 
prevent late effects (92%). Few (13%) believed that follow-up care is not necessary. Two health 
beliefs were associated with follow-up care attendance (perceived benefits: odds ratio [OR]:1.56; 
95% confidence interval [CI]:1.07–2.27; perceived barriers: OR:0.70; 95% CI: 0.50–1.00). 
Conclusions: We show that health beliefs are associated with actual follow-up care attendance of 
adolescent survivors of childhood cancer. A successful model of health promotion in adolescent 
survivors should therefore highlight the benefits and address the barriers to keep adolescent 
survivors in follow-up care. 
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INTRODUCTION 
With increasing survival rates [1], the 
long-term effects of childhood cancer and its 
treatment become apparent. These include second 
malignancies, cardiovascular or endocrine 
problems, and psychological distress [2-4]. In 
order to improve quality of survival and prevent 
long-term effects, regular follow-up visits are 
recommended for most survivors [5,6]. 
While follow-up care attendance has 
been studied in adult survivors of childhood 
cancer [7,8], little is known about the follow-up 
care attendance of adolescent survivors and 
which factors foster or hinder attendance. 
Attending follow-up care might be especially 
important during adolescence to allow for a 
successful transition into adult care [9]. If 
survivors lose contact with their follow-up team 
already in adolesence, they may fail to transition 
to adult care and be lost to follow-up care later in 
life.  
Our objective in the present study was to 
describe follow-up care attendance of adolescent 
survivors of childhood cancer in Switzerland 
within the framework of the Health Belief Model. 
The Health Belief Model (HBM) [10-13] is a 
social cognitive model that has been widely used 
to explain preventive health behavior, such as 
breast-cancer screening, use of sun screen, or use 
of condoms [14-16]. It has also successfully been 
used to predict adolescents’ preventive health-
related behavior such as diabetes management, 
keeping appointments, or use of condoms [17-
20].  
The HBM was developed in the early 
1950s to predict individual health-prevention 
behavior. It contains four main factors: (1) 
perceived susceptibility, the subjective feeling of 
risk or vulnerability to a disease or condition; (2) 
perceived severity, the perceived seriousness of 
contracting an illness; (3) perceived benefits, the 
subjective assessments of the possible advantages 
of potential health behaviors; and (4) perceived 
barriers, the subjective feelings that a health 
behavior might also have negative aspects, such 
as being unpleasant or upsetting. A further factor 
has been added to the model called cues to action 
[16,21]. It can be thought of as a trigger for the 
actual behavior. 
We have used this model previously to 
explore why only a relatively small proportion of 
adult-aged survivors of childhood cancer attend 
regular follow-up care [22]. We found that only 
23% of survivors attended follow-up care and that 
perceived barriers were significantly associated 
with lack of attendance.  
In the present analysis we aimed to (1) 
assess the proportion of adolescent survivors of 
childhood cancer attending follow-up care; (2) 
describe adolescents’ health beliefs; and (3) 
identify the association of health beliefs, 
demographic and medical factors with follow-up 
care attendance. 
METHODS 
Sample and procedure 
The Swiss Childhood Cancer Survivor 
Study (SCCSS) is a nationwide long-term follow-
up study of all patients registered in the Swiss 
Childhood Cancer Registry (SCCR) between 
1976 and 2005, who were Swiss residents at time 
of diagnosis and  survived cancer for 5 years or 
more [23]. The SCCR is a population-based 
registry including all children and adolescents 
diagnosed with leukemia, lymphoma, central 
nervous system (CNS) tumor, malignant solid 
tumor, or Langerhans cell histiocytosis before the 
age of 16 years [24,25]. The SCCSS contains 
three different subgroups who all received 
separate, age-adapted questionnaires : Children 
<16 years of age , adolescents aged 16-19 years, 
and adults aged 20+ years, at the time the 
questionnaire was sent. For the current analyses 
we included only survivors who returned the 
SCCSS questionnaire for adolescents. 
All survivors eligible for the SCCSS 
received an information letter about the study 
from the hospital where they had been treated. 
Letters were written in the corresponding 
language that was registered for the respective 
patient at the hospital (German, French, or 
Italian). A comprehensive address search 
guaranteed that almost all eligible survivors were 
contacted. They were asked to reply if they did 
not wish to participate, if their address had 
changed or if they required the questionnaire in a 
different language other than the one we used in 
the information letter (SupplementalText1). Two 
weeks later all survivors who had not refused to 
participate were sent a questionnaire with a pre-
paid return envelope (Supplemental Text2). Non-
responders received another questionnaire after 
two months and were then contacted by phone 
Follow-up care of adolescent survivors 
Published in final edited form as: Pediatr Blood Cancer. 2016 Feb;63(2):318-25. doi: 10.1002/pbc.25755 
3 
and invited to participate. 
Ethics approval for this study was 
provided through the general cancer registry 
permission of the SCCR (Swiss Federal Expert 
Commission for Professional Secrecy in Medical 
Research) and a non-obstat statement (the ethical 
committee did not object the running of the study) 
was obtained from the cantonal (regional) ethics 
committee of Bern, Switzerland. 
Measures 
The SCCSS used an extensive cross-
sectional questionnaire, similar to major 
childhood cancer survivor studies in the United 
States and the United Kingdom [26,27], assessing 
quality of life, health beliefs, somatic health, 
fertility, current medication and health service 
utilization, health behaviors, and 
sociodemographic information.  
Follow-up care 
In the SCCSS questionaire for 
adolescents, survivors were asked if they were 
still in regular follow-up care for their previous 
cancer (1 = Yes, I still attend regular follow-up 
appointments in the clinic where I was treated, 2 
= Yes, I still have regular follow-up 
appointments, but with a medical doctor outside 
the hospital or at another hospital than the one I 
was treated, 3 = No, regular follow-up is 
completed, but I sometimes visit a doctor for a 
check-up, or 4 = No, regular follow-up is 
completed and I have not seen a doctor for a 
while). For analyses responses (1) and (2) were 
pooled and labeled as attending follow-up, and 
responses (3) and (4) were pooled and labeled as 
not attending follow-up. 
Health beliefs.The questionnaires covered the 
four main HBM dimensions and cues to actions. 
All questions were specifically developed as part 
of the SCCSS. Development included piloting the 
questions with 50 survivors. Questions were 
introduced by inviting survivors to indicate which 
response best describes their own situation on the 
provided likert scales. To measure perceived 
susceptibility we asked suvivor to rate their 
perceived probability of experiencing late effects 
within the next 10 years. Perceived severity was 
assessed with the following item: If I suffer from 
late effects, this will considerably impair my daily 
life. Perceived benefits were captured by asking 
participants to mark the level of their agreement 
with the following item: Regular follow-up care 
may help in detecting late effects and preventing 
negative consequences of late effects of my 
cancer. Perceived barriers were assessed by 
asking participants to mark the level of their 
agreement with the following statements: (1) 
Regular follow-up care is not necessary, and (2) 
At regular follow-up care appointments, I fear 
that negative late effects of my cancer will be 
found. For cues to action we asked (1) if 
participants already suffered from late effects. If 
yes, survivors were asked how severely these late 
effects impair their day-to-day life, and (2) about 
their general health status.   
Sociodemographic characteristics. Survivors 
were asked about their age, gender, their 
educational background (still at school, 
vocational training, work), and the educational 
achievement of their parents (university 
education yes or no) and if they were born in 
Switzerland or abroad [28]. Information was also 
available on the language region (German, 
French, Italian). 
Medical characteristics. Basic medical 
information on diagnoses and treatment of each 
survivor was extracted from the SCCR. 
Diagnoses were classified according to the 
International Classification of Childhood Cancer 
– Third edition [29]. For the regression models, 
diagnoses were pooled into five major groups: 
leukemia, lymphoma, CNS tumors, bone tumors, 
and other solid tumors. Time since diagnosis was 
coded into three categories (5-9 years, 10-14 
years, 15+ years); treatment was coded into 
surgery only, chemotherapy (without 
radiotherapy, may have had surgery), and 
radiotherapy (may have had surgery or 
chemotherapy). We also included information on 
bone marrow transplantation (BMT) and noted if 
the survivor had had a relapse. 
Analyses 
All statistical analyses were conducted 
with STATA 12.1 (College Station, TX). 
Hypotheses testing were done at the 5% 
confidence level, using chi-square and 
likelihood-ratio tests (two-sided tests). First, 
descriptive statistics for follow-up care 
attendance and health beliefs, as well as 
differences in health beliefs between follow-up 
care attendees vs. non-attendees were calculated 
using chi-square tests. Second, we estimated 
univariable logistic regressions of follow-up care 
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attendance on all health-belief, demographic and 
medical factors. Third, we estimated two nested 
multivariable logistic models to account for the 
adjusted effects. One of these models contained 
only demographic and medical factors, while the 
other one also included the health-belief factors 
in order to show if health beliefs have an 
independent effect in addition to demographic 
and medical factors. 
RESULTS 
A total of 781 adolescent survivors were 
eligible (Figure 1). Of these, 696 were contacted 
through valid addresses. We received completed 
questionnaires from 465 (66.8%) survivors (257 
males, 55.3%). The mean age at study (time the 
questionnaire was returned to the study centre) 
was 17.9 years (range: 16-21), the median age at 
diagnosis was five years, and the median time 
since diagnoses was 13 years. The responders had 
been diagnosed with cancer at a younger age than 
non-responders. There were no other significant 
differences between study participants and non-
participants (Table I). 
Follow-up care 
Among the 465 study participants, 410 
responded to the question on follow-up care 
(Figure1). Of these, 195 reported that they attend 
follow-up care at a clinic (47.6%; 95% 
confidence interval [CI]: 42.7-52.4); 34 attend 
follow-up care with a doctor outside the hospital 
(8.3%; 95%CI: 5.6-11.0); 86 were no longer in 
follow-up care but still visit a doctor sometimes 
(21%; 95%CI: 17.0-25.0); and 95 reported not 
having seen a doctor for a while (23.2%; 95%CI: 
19.0-27.0). For the analyses we combined 
answers 1 and 2 as well as 3 and 4: overall,  229 
(55.9%; 95%CI: 51.0-61.0) were labled as 
follow-up care attendees and 181 (44.1%; 
95%CI: 39.3-49.0) as not attending follow-up 
care. 
There was no difference in follow-up 
care attendance by gender (male: 128/227, 
55.4%; female: 101/183, 55.2%; p = 0.81), or 
between those born in Switzerland (203/369; 
55.1%) or abroad (26/41; 63.4%; p = 0.30). There 
were no differences in follow-up care attendance 
according to educational background. Of those in 
vocational training, 53.1% (93/175) reported 
attending follow-up care; of those still at school, 
58.4% (104/178); and of those who were already 
in the labor market, 60.0% (14/23) reported 
attending follow-up care. Parents’ educational 
background was also similar: 58.8% (60/102) of 
those who had at least one parent with university 
degree attended follow-up care vs. 54.9% 
(169/308; p = 0.49) of those who had no parent 
with university degree. 
Health beliefs 
Most survivors (334; 80.3%; 95%CI: 
76.5-84.2) rated their susceptibility (i.e., the 
probability of developing late effects in the next 
10 years) as low (between 0 and 33%). Regarding 
severity, 224 survivors (54.5 %; 95%CI: 49.7-
59.3) believed that late effects would impair their 
lives only slightly or not at all. Most survivors 
agreed moderately or strongly (394; 91.6%; 
95%CI: 89.0-94.3) that follow-up care might 
detect and prevent late effects (benefits). Only 55 
(12.8%; 95%CI: 9.6-15.9) were strongly or 
mostly convinced that follow-up care was 
unnecessary (barriers) (Table II). 
Predictors of follow-up care attendance 
Univariable analyses revealed significant 
associations between follow-up care attendance 
and two of the HBM items (Table III): perceived 
benefits (OR=1.59; 95%CI: 1.18-2.16) and 
barriers, item 1 (OR=0.67; 95%CI: 0.51-0.89). 
The other items were not significantly associated. 
When survivors perceived benefits they were 
more likely to attend follow-up care, and when 
they perceived barriers they were less likely to 
attend. Adolescents closer to time of diagnosis (p 
<0.001) and those who had bone marrow 
transplants were also more likely to attend 
follow-up care (p <0.001). 
Also both multivariable models (Table 
III) showed that the odds of attending follow-up 
care decreased with the amount of time since 
diagnosis (p <0.001) and that type of therapy was 
associated with follow-up visits (p <0.001). 
Treatment with bone marrow transplant was also 
strongly associated with follow-up care 
attendance in both models (model 1: OR=15.21, 
95%CI: 1.87-123-53; model 2: OR=19.15, 
95%CI: 2.25-163.07). In model 2, which also 
included the health belief factors in addition to the 
demographic and medical factors, survivors were 
more likely to attend follow-up care when they 
believed follow-up care was suitable to detect and 
prevent late effects (perceived benefits: 
OR=1.56; 95%CI: 1.07-2.27). In contrast, 
survivors who believed that follow-up care is 
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unnecessary were less likely to attend follow-up 
care (perceived barriers: OR=0.70; 95%CI: 0.50-
1.00). This extended model 2 had a better fit 
according to likelihood ratio testing (χ2(14) = 
67.8; p <0.001). We did not include relapse in the 
models because it correlated perfectly with 
follow-up care attendance—all survivors who 
experienced a relapse reported that they still 
attended follow-up care. 
 
DISCUSSION 
We found that only about half of 
adolescent survivors of childhood cancer still 
attended follow-up care. Health beliefs were 
associated with follow-up care attendance in 
addition to demographic and medical factors. 
Perceived benefits (the belief that follow-up care 
may help to detect and prevent late effects) 
increased the likelihood of attendance, while 
perceived barriers (the belief that follow-up care 
is not necessary) decreased the likelihood. In 
addition, adolescent survivors who were more 
recently diagnosed or had a bone marrow 
transplantation were more likely to attend follow-
up care. All survivors who had a relapse also 
attended follow-up care.  
This study described follow-up care 
attendance in adolescent childhood cancer 
survivors and analyzed the role of demographic 
and medical factors as well as health beliefs. One 
previous study showed that adolescent cancer 
survivors had less positive health beliefs 
compared to healthy peers [30]. Another study 
investigated the association between health 
beliefs and interest in cancer screening among 
adolescent survivors. In that study, survivors who 
rated themselves to be more concerned about 
cancer, more vulnerable to cancer (higher 
susceptibility) and more competent (higher self-
efficacy, a factor not used in the original HBM) 
were more interested in participating in cancer 
screening [31]. An intervention study among 
adolescent childhood cancer survivors showed 
that perceived personal risk for late effects and 
motivation to change health behaviour was 
modifiable and improved with both standard care 
and multi-component test intervention [32,33].  
When comparing the rate of follow-up 
care attendance between the adolescent survivors 
in this study with that in our previous study with 
adults [22], we found that more adolescents 
reported attending follow-up care compared to 
the adults (56% vs. 23%). This may be due to 
adolescent participants being, on average, more 
recently diagnosed (median: 13 years) than were 
the adult participants (median: 20 years). Similar 
to adolescents, for health beliefs, we also found a 
significant association between perceived 
barriers and follow-up visits in adult participants; 
but unlike in adolescent survivors, there was no 
association for perceived benefits. Yet, for the 
adolescents, the perception of benefits from 
attending follow-up also seemed to be important, 
meaning that they need to perceive a positive 
effect in order to pursue a behavior. While most 
adolescent survivor did not report any late effects 
almost half of adult survivors did. The reality that 
most late effects cannot be prevented but only 
detected early might have reduced their belief in 
this kind of benefit of follow-up care. The 
associations between medical factors and follow-
up care attendance are in line with previous 
research on adult survivors of childhood cancer 
[7,34]. 
This study’s main strength is that, for the 
first time, the follow-up care attendance of 
adolescent survivors was investigated and 
analyzed with respect to psychological, 
sociodemographic, and medical characteristics. 
Additionally, we drew upon a population-based 
cohort with a high response rate, increasing the 
reliability of our results. 
However, there are some limitations that 
should be considered. As with all self-report 
questionnaires, participants may not accurately 
remember and report their behavior. Self-
selection is an other potential limitation: it is 
possible that follow-up care attenders were 
overrepresented in our sample, as they may be 
more likely to be interested in the study and return 
the questionnaire. Similarly, participants were on 
average slightly younger than non-participants 
and might thus be more likely to still attend 
follow-up possible because parents are more 
involved in their decisions that for older 
adolescents. Given that we used only cross-
sectional data, causation is unclear: health beliefs 
might have been influenced by earlier follow-up 
visits.The SCCSS included only few questions 
about health beliefs and other important 
dimensions could not be assessed; e.g. barriers 
such as knowledge of the hospital system; or cues 
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to action such as parental support or 
advertisements. Also, self-efficacy - the 
perception that one is competent or capable of 
performing an action to meet a specific goal 
[35,36] - was not assessed. Yet perceptions of 
self-efficacy influence the way people approach 
goals and their persistence when facing 
challenges in health behavior [37,38]. It may be 
important to take this dimension into account 
when designing future research projects in order 
to make more precise predictions about follow-up 
care attendance. Additionally, future research 
should take into account the health beliefs of 
parents who might still have an influence on their 
adolescent children and may directly influence 
the follow-up care attendance of their 
adolescents.  
In Switzerland, follow-up care is well 
organized in pediatric oncology in the first 5 to 10 
years after diagnosis. Thereafter, survivors are 
much more in charge to continue their follow-up 
care. Pediatric oncologists follow survivors long 
into adulthood if necessary. In order to improve 
follow-up care attendance, adolescent survivors’ 
beliefs might be a key factor - beliefs about the 
necessity of follow-up care contribute to 
predicting actual attendance to follow-up care. 
Several models to improve health promotion in 
adolescent survivors have been proposed [39-41]. 
A successful model of health promotion in 
adolescent survivors should therefore highlight 
especially the benefits for adolescent survivors in 
receiving follow-up care, that will also lead to a 
successful transition. The information and 
education about regular follow-up care for young 
survivors and their parents should thus start with 
completion of treatment and educate the 
survivors about the cancer, treatment, potential 
late effects and the importance of follow-up care 
in a age-adapted way [42]. Later on, a well-
organised transition to adult care should follow, 
ideally led by an appointed transition coordinator. 
Benefits of follow-up care should be highlighted 
and possible barriers identified in order to address 
them early and professionally. A survivor 
passport with individually tailored follow-up care 
information is currently developed as a 
collaborative project between ENCCA (European 
Network for Cancer Research in Children and 
Adolescents) and PanCareSurFup (PanCare 
Childhood and Adolescent Cancer Survivor Care 
and Follow-Up Studies) to help survivors to get 
adequate follow-up care. Positive experiences of 
early follow-up appointments might also 
influence later beliefs regarding both benefits and 
barriers. 
In this analysis, we showed that 
adolescent survivors’ health beliefs are associated 
with follow-up care attendance. We suggest that 
regular information on the importance, 
effectiveness, and necessity of long-term follow-
up care should be given to patients and their 
parents starting at the conclusion of therapy. 
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TABLE I. Differences Between Study Participants and Non-Participants 
 
 Participants (n = 410) 
Non-
participants 
(n = 286) 
p(χ2) 
 n % n %  
Sex      
Male 227 55.4 172 60.1  
Female 183 44.6 114 39.9 0.210 
Age at studya      
16 50 12.2 23 8.1  
17 113 27.6 69 24.2  
18 127 31.0 68 23.9  
19 68 16.6 61 21.4  
20 42 10.2 47 16.5  
21 10 2.4 15 5.3  
22 0 0.0 2 0.70 <0.001 
Language      
German 279 68.0 198 69.2  
French 117 28.5 74 25.9  
Italian 14 3.4 14 4.9 0.500 
Age at diagnosis (years)      
0-4 209 51.0 134 46.9  
5-7 87 21.2 56 19.6  
8-11 88 21.5 66 23.1  
12-14 26 6.30 30 10.5 0.203 
Time since diagnosis (years)      
5-9 91 22.2 72 25.2  
10-14 135 32.9 97 33.9  
15+ 184 44.9 117 40.9 0.522 
Diagnosis      
Leukemia 135 32.9 92 32.2  
Lymphoma 52 12.7 30 10.5  
Central nervous system tumor 69 16.8 57 19.9  
Neuroblastoma 24 5.9 19 6.6  
Retinoblastoma 15 3.7 11 3.8  
Renal tumors 41 10.0 15 5.2  
Hepatic tumors 2 0.5 2 0.7  
Bone tumor 13 3.2 12 4.2  
Soft tissue sarcoma 20 4.9 15 5.2  
Germ cell tumor 14 3.4 8 2.8  
Other tumor 4 1.0 6 2.1  
Langerhans cell histiocytosis 21 5.1 19 6.6 0.570 
Treatment      
Chemotherapyb 225 56.3 152 53.9  
Radiotherapyc 112 28.0 70 24.8  
Surgery only 63 15.8 60 21.3 0.166 
Bone marrow transplant      
No 392 95.6 269 94.1  
Yes 18 4.4 17 5.9 0.356 
Relapse      
No 406 99.0 281 98.3  
Yes 4 1.0 5 1.7 0.375 
a Age at study for non-participants refers to the last date they were contacted, b With or without surgery,c With or 
without chemotherapy or surgery  
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TABLE II. Health Beliefs in Follow-Up Care Attendees and Non-Attendees 
 
 Total Do not attend FU Attend FU p(χ2) n n % n % 
Susceptibility: probability for late effects       
0% 32 15 9.2 17 8.1  
1-33% 268 119 73.0 149 71.0  
34-66% 47 19 11.7 28 13.3  
67-100% 26 10 6.1 16 7.6 0.878 
Missing 37 18  19   
Severity: late effects will impair life       
Not at all 49 21 13.2 28 13.5  
Slightly 152 62 39.0 90 43.5  
Moderately 101 49 30.8 52 25.1  
A lot 64 27 17.0 37 17.9 0.673 
Missing 44 22  22   
Benefits: follow-up detects and prevents late effects       
Strongly disagree 13 7 4.3 6 2.7  
Mostly disagree 18 10 6.1 8 3.6  
Mostly agree 115 61 37.4 54 24.5  
Strongly agree 237 85 52.1 152 69.1 0.010 
Missing 27 18  9   
Barriers I: follow-up is not necessary       
Strongly disagree 238 93 56.4 145 66.2  
Mostly disagree 101 45 27.3 56 25.6  
Mostly agree 27 14 8.5 13 5.9  
Strongly agree 18 13 7.9 5 2.3 0.033 
Missing 26 16  10   
Barriers II: fear of detecting late effects       
Strongly disagree 180 79 48.2 101 46.1  
Mostly disagree 105 48 29.3 57 26.0  
Mostly agree 66 25 15.2 41 18.7  
Strongly agree 32 12 7.3 20 9.1 0.689 
Missing 27 17  10   
Cues to action: self-reported late effects       
No 266 133 76.0 133 59.6  
Yes 132 42 24.0 90 40.4 0.001 
Missing 12 6  6   
Cues to action: how severe are current late effectsa       
Not at all 54 28 42.4 26 24.1  
Slightly 70 20 30.3 50 46.3  
Moderately 35 16 24.2 19 17.6  
A lot 15 2 3.0 13 12.0 0.008 
Missing 2 0  2   
Cues to action: current health       
Poor 0 0 0.0 0 0.0  
Fair 15 5 2.8 10 4.4  
Good 85 38 21.0 47 20.7  
Very good 180 86 47.5 94 41.4  
Excellent 128 52 28.7 76 33.5 0.509 
Missing 2 0   2     
a Only survivors who reported current late effects; FU: follow-up care 
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TABLE III. Predictors of Follow-Up Care Attendance 
 
 Univariable logistic regressions 
Multivariable logistic regressions 
Model 1: Demographic and 
medical factors 
Model 2: Health-beliefs, 
demographic, and medical factors 
OR 95% CI pa OR 95% CI pa OR 95% CI pa 
Health-beliefsb          
Susceptibility 1.00  0.99-1.01  0.678    1.01  0.99-1.02  0.448 
Severity 0.93  0.73-1.17  0.526    0.86  0.65-1.13  0.147 
Benefits 1.59  1.18-2.16  0.002    1.56  1.07-2.27  0.017 
Barriers I 0.67  0.51-0.89  0.004    0.70  0.50-1.00  0.041 
Barriers II 0.99  0.80-1.23  0.914    0.98  0.75-1.28  0.677 
Late effects 1.08  0.90-1.31  0.398    1.08  0.87-1.35  0.268 
Health status 0.94  0.72-1.22  0.645    1.16  0.83-1.63  0.560 
Demographic characteristics          
Female 0.95  0.62-1.46  0.806 1.03  0.64-1.66  0.889 0.99  0.60-1.66  0.780 
Born abroad 1.43  0.66-3.08  0.357 0.67  0.28-1.60  0.527 0.67  0.27-1.65  0.512 
Language (vs. German)          
French 1.00  0.62-1.62   0.83  0.48-1.43   0.71  0.40-1.28   
Italian 0.91  0.27-3.07  0.989 0.55  0.13-2.25  0.600 0.38  0.09-1.61  0.266 
Age at study 0.90  0.75-1.08  0.243 0.95  0.77-1.18  0.074 0.94  0.76-1.18  0.161 
Medical characteristics          
Time since diagnosis (vs. 5-9 
years)          
10-14 years 0.28  0.14-0.58   0.24  0.11-0.52   0.21  0.10-0.47   
15+ years 0.13  0.06-0.26  <0.001 0.11  0.05-0.24  <0.001 0.10  0.05-0.23  <0.001 
Cancer diagnosis (vs. leukemia)          
Lymphoma 1.38  0.68-2.80   0.84  0.37-1.91   0.75  0.32-1.72   
CNS tumor 1.89  0.94-3.78   1.47  0.61-3.56   1.60  0.63-4.05   
Bone tumor 1.85  0.80-4.25   2.37  0.91-6.15   2.56  0.92-7.13   
Other tumor 0.73  0.42-1.25  0.035 0.99  0.54-1.83  0.316 0.98  0.52-1.85  0.231 
Therapy (vs. chemotherapyc)          
Radiotherapyd 1.74  1.05-2.90   1.42  0.78-2.59   1.63  0.87-3.06   
Surgery only 1.00  0.53-1.87  0.083 0.74  0.32-1.67  <0.001 0.89  0.37-2.11  <0.001 
Had bone marrow transplantation 12.30  1.61-94.25  <0.001 15.21  1.87-123.53  0.002 19.15  2.25-163.07  0.001 
N   340   340   340 
Overall p      <0.001   <0.001 
a p refers to likelihood ratio testing, b Susceptibility: for having late effects in the next 10 years; Severity: “If I suffer from late effects, this will considerably impair my life;” 
Benefits: “Regular follow-up may help in detecting late effects and preventing negative consequences of late effects;” Barriers: (I) “Regular follow-up is not necessary” and 
(II) “At regular follow-up appointments, I fear that negative late effects of my cancer will be found.”, c With or without surgery, d With or without chemotherapy or surgery, 
CI: confidence interval; OR: odds ratio, N: number of subjects in analyses 
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Figure 1. Participants in Analysis  
Eligible survivors: Eligible for the SCCSS adolescent questionnaire (aged 16-19 at time of first 
contact ) 
 
 
  
Eligible survivors  
N = 781 
Traced and sent questionnaires 
n = 696 (89.1%)  
Not contacted yet at time of analyses 
n =  57 (7.3%)  
No current address available 
n = 28 (3.5%)  
Did not respond to follow-up care questions 
n = 55  (7.9%)  
Did not respond  
n = 97 (28.3%)  
Refused to participate  
n = 34 (4.9%)  
Returned questionnaire 
n = 465 (66.8%)  
Available for analyses 
N= 410 (58.9%)   
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Supplemental Material In this file we present the information letter sent to the survivors before the study and the letter we sent together with the questionnaire (each letter was available in German, French and Italian). Each letter was signed by the head of the pediatric oncology clinic where the survivor was treated for their cancer and by the head of the Swiss Childhood Cancer Registry and the Swiss Childhood Cancer Survivor Study. 
Supplemental Text 1: Information letter from paediatric oncology clinic 
German 
Vorankündigung: Gesundheitsbefragung nach Erkrankung im Kindes- und 
Jugendalter 
 Si vous ne parlez pas l’allemand veuillez lire les informations sur la feuille jointe. Lieber Vorname Nachname Sie waren in unserer Kinderklinik in Behandlung wegen einer Leukämie, Tumorerkrankung (auch gutartig) oder einer anderen seltenen Erkrankung. Um die bestmögliche Betreuung dieser seltenen Krankheiten zu garantieren, ist der Wissensaustausch zwischen Ärzten extrem wichtig. Daher wird seit 1976 die Behandlung dieser Erkrankungen im Schweizer Kinderkrebsregister ausgewertet (www.kinderkrebsregister.ch). Dank dieser Zusammenarbeit von Ärzten und Wissenschaftlern wurden enorme Fortschritte gemacht, so dass heute die meisten krebskranken Kinder geheilt werden. Wir wissen aber, dass bei gewissen Patienten Jahre nach erfolgreicher Behandlung Gesundheitsprobleme auftreten können. Eine Früherkennung dieser Spätfolgen ermöglicht es oft, Komplikationen zu vermeiden oder zu mildern.  Aus diesem Grund kontaktieren wir alle betroffenen Personen in der Schweiz und werden auch Ihnen innerhalb der nächsten zwei Wochen einen Fragebogen schicken. Bisher haben wir schon über 2500 Fragebogen zurückbekommen. Falls Sie den Fragebogen in einer anderen Sprache wünschen oder uns eine Adressberichtigung mitteilen möchten, bitten wir Sie um eine kurze Rückmeldung. Die 
Kontaktpersonen für die Studie sind: NAME, Schweizer Kinderkrebsregister, Institut für Sozial- und Präventivmedizin, Finkenhubelweg 11, 3012 Bern; E-Mail: , Tel:.  Wenn wir nichts von Ihnen hören, werden wir Ihnen den Fragebogen innerhalb der nächsten zwei Wochen zuschicken. Ganz herzlichen Dank schon jetzt, denn Ihre Mitarbeit wird uns helfen, die Behandlung von krebskranken Kindern weiter zu verbessern. Mit freundlichen Grüssen Abteilungsleiter Päd. Hämato-/Onkologie Leiterin Schweizer Kinderkrebsregister  
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French:  
Annonce: Questionnaire de santé après une maladie durant l’enfance ou 
l’adolescence 
 Falls Sie kein Französisch sprechen, lesen Sie bitte die Informationen auf dem beigelegten Blatt. Cher „Vorname“ „Nachname“ Chère „Vorname“ „Nachname“ Vous avez été traité(e) dans notre Unité d’Oncologie pédiatrique pour une leucémie, une tumeur (bénigne ou maligne) ou une autre maladie rare. Afin de garantir le meilleur traitement possible pour ces maladies rares, l’échange d’informations entre les médecins est extrêmement important. C’est pour cette raison que, depuis 1976, le suivi de ces maladies est analysé par le Registre Suisse du Cancer de l’Enfant (www.registretumeursenfants.ch). Cette collaboration entre médecins et chercheurs a permis d’immenses progrès: aujourd’hui, la majorité des enfants atteints de cancer peut être guérie. Nous savons cependant que des problèmes de santé peuvent survenir chez certains patients des années après le traitement. Grâce à un dépistage soigneux de ces effets tardifs, il est souvent possible d’éviter des conséquences graves ou au moins de les traiter à temps et ainsi les atténuer. C’est pour cette raison que nous vous contactons, ainsi que toutes les personnes concernées en Suisse, et vous enverrons un questionnaire. Jusqu’à présent, plus de 2500 questionnaires nous ont déjà été retournés. Si vous préférez le questionnaire dans une autre langue ou souhaitez nous indiquer une correction d‘adresse, nous vous prions de nous contacter. Les personnes à contacter pour l‘étude sont : NAME, Registre Suisse du Cancer de l‘Enfant, Institut de Médecine Sociale et Préventive, Finkenhubelweg 11, 3012 Berne; e-mail:  , tél:  .  Si nous n’entendons rien de votre part, nous vous enverrons le questionnaire dans les prochains jours. Nous vous remercions déjà de votre collaboration, qui nous aidera à améliorer continuellement le suivi des enfants atteints d’un cancer. Avec nos meilleures salutations Médecin-chef Hématologie / Oncologie pédiatrique  Directrice du Registre Suisse du Cancer de l’Enfant 
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Italian:  
Questionario dopo malattia in età pediatrica Spettabile Signor/Signora ……………….. Come già annunciato, troverà in allegato il questionario sulla sua salute. È diretto ad adolescenti e giovani adulti, i quali durante l’infanzia si sono ammalati di una leucemia, di un tumore solido (anche benigno) o di un’altra malattia rara. I risultati di questa inchiesta ci aiuteranno a ottimizzare il trattamento dei bambini malati di cancro, come pure a migliorare il depistaggio precoce dei possibili effetti a lungo termine dovuti al trattamento.  L’inchiesta è condotta dal Gruppo Svizzero di Oncologia Pediatrica (SPOG) e dall’istituto di medicina preventiva e sociale dell’Università di Berna, e sostenuta da associazioni di pazienti e genitori (Kinderkrebshilfe Schweiz, Swiss Childhood Cancer Survivors, Lega contro il Cancro). Troverà ulteriori informazioni sullo studio e sul registro del cancro dei bambini sul sito www.kinderkrebsregister.ch. I risultati di quest’analisi aiuteranno a migliorare ulteriormente la cura dei tumori nei bambini e la loro presa a carico dopo la terapia. Ci rendiamo conto che per alcuni di voi non risulterà facile compilare il questionario; potrebbero riaffiorare alcuni ricordi dolorosi. Ragion per cui le siamo ancora più riconoscenti se potesse darci il suo importante contributo e feedback. Solo se riceviamo il maggior numero di risposte, i nostri risultati saranno significativi. Naturalmente i suoi dati saranno gestiti in maniera confidenziale e anonima.  Se non riuscisse a compilare il questionario da solo, le saremmo grati se persone vicine a lei la possano aiutare. Per eventuali difficoltà o domande non esiti a contattare NAME: tel., e-mail:). Può rispedirci il suo questionario gratuitamente con la busta già affrancata in allegato. La ringraziamo sin d’ora e le porgiamo i nostri più cordiali saluti.   
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Supplemental Text2: Cover letter sent with the questionnaire 
German:  
Gesundheitsbefragung nach Erkrankung im Kindes- und Jugendalter Lieber Vorname Nachname Wie angekündigt senden wir Ihnen den Fragebogen zu Ihrer Gesundheit. Er richtet sich an Kinder, Jugendliche und junge Erwachsene, welche im Kindes- oder Jugendalter eine Leukämie, Tumorerkrankung (auch gutartig) oder eine andere seltene Erkrankung hatten. Die Untersuchung wird von der Schweizerischen Pädiatrischen Onkologiegruppe (SPOG) und dem Institut für Sozial- und Präventivmedizin der Universität Bern durchgeführt, unterstützt von Patienten- und Elternvereinigungen (Kinderkrebshilfe Schweiz, Swiss Childhood Cancer Survivors, Krebsliga). Weitere Informationen über die Studie und das Kinderkrebsregister finden Sie unter: www.kinderkrebsregister.ch. Die Ergebnisse dieser Untersuchung werden helfen, die Krebsbehandlung bei Kindern weiter zu optimieren, sowie die Nachsorge zu verbessern. Es ist uns bewusst, dass einigen von Ihnen das Ausfüllen des Fragebogens nicht leicht fällt; vielleicht werden schmerzliche Erinnerungen geweckt. Umso dankbarer sind wir, wenn Sie uns trotzdem dieses wichtige Feedback geben. Nur wenn wir möglichst viele Antworten erhalten sind die Ergebnisse der Untersuchung aussagekräftig. Falls Sie den Fragebogen nicht selber ausfüllen können, sind wir dankbar, wenn Verwandte oder Freunde dabei helfen. Bei Schwierigkeiten oder Fragen beim Ausfüllen dürfen Sie sich gerne an NAME wenden (Tel:; E-Mail:). Selbstverständlich werden wir Ihre Angaben streng vertraulich behandeln und nur anonym auswerten.  Sie können den Bogen gratis im beigelegten vorfrankierten Couvert zurücksenden.  Mit freundlichen Grüssen und ganz herzlichem Dank im Voraus Abteilungsleiter Päd. Hämato-/Onkologie Leiterin Schweizer Kinderkrebsregister   
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French:  
Questionnaire de santé après une maladie grave durant l’enfance ou l’adolescence Cher / Chère NAME Comme annoncé dans un courrier précédent, nous vous envoyons le questionnaire sur votre état de santé: il s’adresse aux adolescents et aux jeunes adultes qui ont été atteints d’une leucémie, d’une maladie tumorale (bénigne ou maligne) ou d’une autre maladie rare. Cette recherche est menée par le Groupe d’Oncologie Pédiatrique Suisse (SPOG) et par l’Institut de Médecine Sociale et Préventive de l’Université de Berne. Nous avons le soutien de plusieurs organisations de patients et de parents (Kinderkrebshilfe Schweiz, Swiss Childhood Cancer Survivors, Ligue Suisse Contre le Cancer). Vous trouverez plus d’informations sur l’étude et le Registre Suisse du Cancer de l’Enfant sur: www.registretumeursenfants.ch. Les résultats de cette enquête contribueront à l’amélioration du traitement et le suivi du cancer des enfants. Nous savons que, pour certains d’entre vous, il ne sera pas forcément facile de remplir ce questionnaire; peut-être que de souvenirs douloureux seront réveillés. Nous vous sommes d’autant plus reconnaissants de votre participation, qui est si importante. Seules des réponses d’une grande majorité des personnes concernées peuvent garantir la validité des résultats de cette recherche. Si vous ne pouvez pas remplir le questionnaire vous-même, demandez de l’aide à des membres de votre famille ou à des amis. En cas de difficulté ou si vous avez des questions au moment du remplissage, vous pouvez vous adresser à NAME (tél:; e-mail:) Vos données seront bien sûr traitées de manière strictement confidentielle et analysées anonymement.  Vous pouvez nous retourner votre questionnaire gratuitement dans l’enveloppe-réponse ci-jointe.  Avec nos meilleures salutations et nos remerciements anticipés Médecin-chef Hématologie / Oncologie pédiatrique  Directrice du Registre Suisse du Cancer de l’Enfant   
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Italian:  
Questionario dopo malattia in età pediatrica Spettabile Signor/Signora ……………….. Come già annunciato, troverà in allegato il questionario sulla sua salute. È diretto ad adolescenti e giovani adulti, i quali durante l’infanzia si sono ammalati di una leucemia, di un tumore solido (anche benigno) o di un’altra malattia rara. I risultati di questa inchiesta ci aiuteranno a ottimizzare il trattamento dei bambini malati di cancro, come pure a migliorare il depistaggio precoce dei possibili effetti a lungo termine dovuti al trattamento.  L’inchiesta è condotta dal Gruppo Svizzero di Oncologia Pediatrica (SPOG) e dall’istituto di medicina preventiva e sociale dell’Università di Berna, e sostenuta da associazioni di pazienti e genitori (Kinderkrebshilfe Schweiz, Swiss Childhood Cancer Survivors, Lega contro il Cancro). Troverà ulteriori informazioni sullo studio e sul registro del cancro dei bambini sul sito www.kinderkrebsregister.ch. I risultati di quest’analisi aiuteranno a migliorare ulteriormente la cura dei tumori nei bambini e la loro presa a carico dopo la terapia. Ci rendiamo conto che per alcuni di voi non risulterà facile compilare il questionario; potrebbero riaffiorare alcuni ricordi dolorosi. Ragion per cui le siamo ancora più riconoscenti se potesse darci il suo importante contributo e feedback. Solo se riceviamo il maggior numero di risposte, i nostri risultati saranno significativi. Naturalmente i suoi dati saranno gestiti in maniera confidenziale e anonima.  Se non riuscisse a compilare il questionario da solo, le saremmo grati se persone vicine a lei la possano aiutare. Per eventuali difficoltà o domande non esiti a contattare la NAME: tel., e-mail: ). Può rispedirci il suo questionario gratuitamente con la busta già affrancata in allegato. Spec. FMH pediatria e oncologia pediatrica  Direttrice Registro Svizzero Tumori Pediatrici   
 
